On April 20, 2022 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentations by members of its management team at several industry and scientific conferences during April and May 2022 (Press release, ImmuneTune, APR 20, 2022, View Source [SID1234612539]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am glad to announce that we have been selected to present at the Neoantigen Summit and the Cancer Immunotherapy meeting," said Sijme Zeilemaker, CEO of Immunetune. "As our lead program NeoVAC has recently completed GLP toxicity studies, we are looking forward to present our preclinical package and connect with other leaders in this exciting industry of immunotherapies for the treatment of cancer."
Upcoming conferences:
Innovation for Health, April 21, Amsterdam, the Netherlands
CEO Sijme Zeilemaker will be participating.
Neoantigen Summit Europe, April 26 – 28, Amsterdam, the Netherlands
CEO Sijme Zeilemaker will take part in the Industry Leader’s Fireside Chat on April 27th, 10:40 – 11:00 AM, on the great challenges and opportunities in cancer vaccine development.
CSO Jeroen van Bergen will be presenting on April 27th, 12:00 – 12:30 PM, on ‘Optimizing Vaccine Manufacturing for Targeting Neoantigens’ in the Clinical Translation & Manufacturing track.
Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper) Annual Meeting, May 10-12, Mainz, Germany
CSO Jeroen van Bergen will be giving a poster presentation on May 10th between 3:30 – 6:00 PM.
CSO Jeroen van Bergen will be giving an oral presentation in the short-talk session presenting on on May 12th between 9:00 – 10:30 AM.
The selected abstract for both sessions is titled "Personalized synthetic polyepitope DNA cancer vaccines including a novel pyroptotic adjuvant synergize with checkpoint inhibitor therapy to generate effective anti-tumor T cell immunity". Abstracts will be available online prior to the start of the conference.
Knowledge for Growth, May 19, Ghent, Belgium
CEO Sijme Zeilemaker will be participating.